{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:07:02Z","timestamp":1784005622446,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s10741-018-9760-6","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T20:57:37Z","timestamp":1546981057000},"page":"309-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Subcutaneous furosemide for the treatment of heart failure: a state-of-the art review"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2881-3754","authenticated-orcid":false,"given":"Maxwell Eyram","family":"Afari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Aoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarthak","family":"Khare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"key":"9760_CR1","first-page":"e29","volume":"131","author":"D Mozaffarian","year":"2015","unstructured":"Mozaffarian D, Benjamin EJ, Go AS et al (2015) Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation 131:e29\u2013e322","journal-title":"Circulation"},{"key":"9760_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.cardfail.2014.12.002","volume":"21","author":"A Vidic","year":"2015","unstructured":"Vidic A, Chibnall JT, Hauptman PJ (2015) Heart failure is a major contributor to hospital readmission penalties. J Card Fail 21:134\u2013137","journal-title":"J Card Fail"},{"key":"9760_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.7326\/0003-4819-102-3-314","volume":"102","author":"MR Vasko","year":"1985","unstructured":"Vasko MR, Cartwright DB, Knochel JP, Nixon JV, Brater DC (1985) Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 102:314\u2013318","journal-title":"Ann Intern Med"},{"key":"9760_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0002-9343(98)00111-9","volume":"104","author":"SS Gottlieb","year":"1998","unstructured":"Gottlieb SS, Khatta M, Wentworth D, Roffman D, Fisher ML, Kramer WG (1998) The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. Am J Med 104:533\u2013538","journal-title":"Am J Med"},{"key":"9760_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1017\/S1047951101000270","volume":"11","author":"K Harada","year":"2001","unstructured":"Harada K, Tamura M, Yasuoka K, Toyono M (2001) A comparison of tissue Doppler imaging and velocities of transmitral flow in children with elevated left ventricular preload. Cardiol Young 11:261\u2013268","journal-title":"Cardiol Young"},{"key":"9760_CR6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1345\/aph.1D332","volume":"38","author":"AK Verma","year":"2004","unstructured":"Verma AK, da Silva JH, Kuhl DR (2004) Diuretic effects of subcutaneous furosemide in human volunteers: a randomized pilot study. Ann Pharmacother 38:544\u2013549","journal-title":"Ann Pharmacother"},{"key":"9760_CR7","doi-asserted-by":"crossref","unstructured":"Galindo-Ocana J, Romero-Mena J, Castillo-Ferrando JR et al. (2013) Subcutaneous furosemide as palliative treatment in patients with advanced and terminal-phase heart failure. BMJ Support Palliat Care 3:7\u20139","DOI":"10.1136\/bmjspcare-2012-000296"},{"key":"9760_CR8","doi-asserted-by":"crossref","unstructured":"Austin J, Hockey D, Williams WR et al. (2013) Assessing parenteral diuretic treatment of decompensated heart failure in the community. Br J Community Nurs 18:528, 530-4","DOI":"10.12968\/bjcn.2013.18.11.528"},{"key":"9760_CR9","doi-asserted-by":"crossref","unstructured":"Sica DA, Muntendam P, Myers RL, ter Maaten JM, Sale ME, de Boer RA, Pitt B (2018) Subcutaneous furosemide in heart failure:pharmacokinetic characteristics of a newly buffered solution. JACC Basic Transl Sci 3:25\u201334","DOI":"10.1016\/j.jacbts.2017.10.001"},{"key":"9760_CR10","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1345\/aph.1E172","volume":"38","author":"MA Goenaga","year":"2004","unstructured":"Goenaga MA, Millet M, Sanchez E, Garde C, Carrera JA, Arzellus E (2004) Subcutaneous furosemide. Ann Pharmacother 38:1751","journal-title":"Ann Pharmacother"},{"key":"9760_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1177\/1049909112465795","volume":"30","author":"LB Farless","year":"2013","unstructured":"Farless LB, Steil N, Williams BR, Bailey FA (2013) Intermittent subcutaneous furosemide: parenteral diuretic rescue for hospice patients with congestive heart failure resistant to oral diuretic. Am J Hosp Palliat Care 30:791\u2013792","journal-title":"Am J Hosp Palliat Care"},{"key":"9760_CR12","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1177\/0269216311399490","volume":"25","author":"H Zacharias","year":"2011","unstructured":"Zacharias H, Raw J, Nunn A, Parsons S, Johnson M (2011) Is there a role for subcutaneous furosemide in the community and hospice management of end-stage heart failure? Palliat Med 25:658\u2013663","journal-title":"Palliat Med"},{"key":"9760_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/bmjspcare-2012-000296","volume":"3","author":"J Galindo-Ocana","year":"2013","unstructured":"Galindo-Ocana J, Romero-Mena J, Castillo-Ferrando JR, Aguilera-Gonzalez C, Bernabeu-Wittel M, Ollero-Baturone M (2013) Subcutaneous furosemide as palliative treatment in patients with advanced and terminal-phase heart failure. BMJ Support Palliat Care 3:7\u20139","journal-title":"BMJ Support Palliat Care"},{"key":"9760_CR14","doi-asserted-by":"crossref","unstructured":"Picazo Sanchez M, Castillo Lorenzo MN, Cuxart Perez M, Sans Lorman R (2018) Palliative use of furosemide in continuous subcutaneous infusion in a renal transplant patient with heart failure. Nefrologia 38:438\u2013439","DOI":"10.1016\/j.nefroe.2017.11.020"},{"key":"9760_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2015.06.017","volume":"4","author":"LF Buckley","year":"2016","unstructured":"Buckley LF, Carter DM, Matta L, Cheng JW, Stevens C, Belenkiy RM, Burpee LJ, Young MA, Weiffenbach CS, Smallwood JA, Stevenson LW, Desai AS (2016) Intravenous diuretic therapy for the Management of Heart Failure and Volume Overload in a multidisciplinary outpatient unit. JACC Heart Fail 4:1\u20138","journal-title":"JACC Heart Fail"},{"key":"9760_CR16","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.recesp.2013.06.010","volume":"66","author":"E Zatarain-Nicolas","year":"2013","unstructured":"Zatarain-Nicolas E, Lopez-Diaz J, de la Fuente-Galan L, Garcia-Pardo H, Recio-Platero A (2013) San Roman-Calvar JA. Subcutaneous infusion of furosemide administered by elastomeric pumps for decompensated heart failure treatment: initial experience. Rev Esp Cardiol (Engl Ed) 66:1002\u20131004","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"9760_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jchf.2017.10.001","volume":"6","author":"NA Gilotra","year":"2018","unstructured":"Gilotra NA, Princewill O, Marino B, Okwuosa IS, Chasler J, Almansa J, Cummings A, Rhodes P, Chambers J, Cuomo K, Russell SD (2018) Efficacy of intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure. JACC Heart Fail 6:65\u201370","journal-title":"JACC Heart Fail"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-018-9760-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-018-9760-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-018-9760-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T19:10:29Z","timestamp":1578424229000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-018-9760-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["9760"],"URL":"https:\/\/doi.org\/10.1007\/s10741-018-9760-6","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,8]]},"assertion":[{"value":"8 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None of the authors has any conflict of interest related to the contents of this manuscript. Lana Tsao has received research grant from SC Pharmaceuticals Inc. (developers of the proprietary furosemide infusor) for an ongoing clinical trial. None of the coauthors have any disclosures to make.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}